Exicure (NASDAQ:XCUR – Get Free Report) and United Therapeutics (NASDAQ:UTHR – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.
Insider and Institutional Ownership
42.8% of Exicure shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 8.6% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Exicure and United Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Exicure | N/A | -237.91% | -61.98% |
| United Therapeutics | 38.61% | 19.18% | 17.07% |
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Exicure and United Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Exicure | 1 | 0 | 0 | 0 | 1.00 |
| United Therapeutics | 1 | 3 | 12 | 0 | 2.69 |
United Therapeutics has a consensus target price of $676.40, indicating a potential upside of 21.93%. Given United Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe United Therapeutics is more favorable than Exicure.
Volatility & Risk
Exicure has a beta of 3.83, suggesting that its stock price is 283% more volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.
Earnings and Valuation
This table compares Exicure and United Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Exicure | $500,000.00 | 11.79 | -$4.95 million | ($1.32) | -0.68 |
| United Therapeutics | $3.18 billion | 7.42 | $1.33 billion | $26.50 | 20.93 |
United Therapeutics has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
United Therapeutics beats Exicure on 11 of the 14 factors compared between the two stocks.
About Exicure
Exicure, Inc. is a biotechnology company historically focused on developing nucleic acid-based therapeutics. Its research has centered on spherical nucleic acid (SNA) technology, a platform designed to deliver genetic material into cells and influence disease-related gene activity. The company has pursued potential treatments for conditions including rare genetic disorders and cancer. Its work has included research into therapies intended to address diseases with limited treatment options. Exicure was based in Chicago, Illinois.
About United Therapeutics
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
